

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. : WARF-0002

Inventors: Laughon, Allen S.

Serial No. : 09/810,385

Filing Date: March 16, 2001

Examiner: Harris, Alana M.

Customer No. : 26259

Group Art Unit: 1643

Confirmation No. : 8778

Title: Compositions and Methods for Negative Regulation of TGF- β Pathways

Express Mail Label No. EV794825581US

Date of Deposit December 12, 2005

I hereby certify that this paper is being deposited with the United States Postal Service Express Mail Post Office to Addressee service under 37 CFR 1.10 on the date indicated above and is addressed to the Mail Stop AF Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By Jane Massey
Typed Name: Jane Massey Licata, Reg. No. 32,257

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RULE 132 DECLARATION

1. I, Dr. Allen S. Laughon, Ph.D. am the inventor in U.S. Patent Application Serial No. 09/810,385 filed March 16, 2001 and am most familiar with the subject matter of this application and the research effort which lead to the discovery of the instant invention.


2. As described in the '385 application at pages 14 and 15, a cell-based reporter assay has been used to identify compounds that interfere with transcriptional repression of genes induced by a TGF- β , activin or bone morphogenetic protein signal in cells. The components

Attorney Docket No.: WARF-0002
Inventors: Laughon, Allen S.
Serial No.: 09/810,385
Filing Date: March 16, 2001
Page 2

used in the assay were known at the time of filing of the '385 application and are those described in the '385 application and depicted in Figure 6, namely Mad and Medea as Smad proteins, Shn as the DNA-binding Smad co-repressor protein, dCtBP, and lacZ as the reporter, the expression of which is controlled by the *brk* promoter, a direct target of Mad/Medea and Schnurri (see abstract of Muller et al. (2003) Cell 113:221– 233; Exhibit A).

The results of this assay (see Exhibit B) show that a mutant version of the adenovirus E1A protein (designated in Exhibit B as pPACE1A), which is a documented inhibitor of CtBP, blocks repression of the *brk-lacZ* reporter construct in transiently transfected Drosophila S2 cells. In this assay, repression of the *brk-lacZ* reporter is caused by cotransfection of a plasmid that expresses TkvQD, an activated form of the type I Dpp receptor. Cotransfection with a plasmid expressing E1A blocks this repression by inhibiting CtBP. Accordingly, having used the well-known assay components and guidance provided in the specification for carrying out the method of the '385 application, we have successfully identified a compound that interferes with transcriptional repression of genes induced by a TGF-13, activin or bone morphogenetic protein signal in cells.

I hereby declare that all statements herein of our own knowledge are true and that all statements made on information or belief are believed to be true; and further that these statements were made with the knowledge that willful statements and the like so made are punishable by fine or by imprisonment, or both under §1001 of Title 18 or the United States Code, and that such willful statements may jeopardize the validity of the application, any patent issuing there upon or any patent to which this verified statement is directed.



Dr. Allen S. Laughon, Ph.D.

Date: Dec. 9, 2005